BusinessAdamas Announces U.S. Commercial Launch of GOCOVRI™ the First and Only FDA-approved Medication for the Treatment of Dyskinesia in Parkinson’s Disease PatientsBy Nasdaq OMXJan 8, 2018, 9:41 PM UTC
BusinessAdamas Reports Recent Achievements and Third Quarter 2017 Financial ResultsBy Nasdaq OMXNov 2, 2017, 8:02 PM UTC
BusinessNeuroDerm to Host Fourth Quarter and 2015 Fiscal Year Financial Results Conference Call on March 31, 2016By Nasdaq OMXMar 22, 2016, 11:00 AM UTC
